MISSION

The Breast Cancer Research Foundation (BCRF) is committed to being the end of breast cancer by advancing the world’s most promising research. Founded by Evelyn H. Lauder in 1993, BCRF-funded investigators have been deeply involved in every major breakthrough in breast cancer research. By committing 91 cents of every dollar directly to its mission, BCRF remains one of the nation’s most fiscally responsible nonprofits. BCRF is the only breast cancer organization in the US with an “A+” from CharityWatch and has been awarded Charity Navigator’s highest rating of four stars 14 times since 2002.

Visit www.bcrfcure.org to learn more.
A LETTER FROM BCRF LEADERSHIP

Evelyn H. Lauder established the Breast Cancer Research Foundation because she saw an urgent need for an organization exclusively dedicated to advancing research. Since then, BCRF’s global network of investigators has been deeply involved in every major breakthrough in breast cancer prevention, diagnosis, treatment, metastasis and survivorship. This year alone we have awarded $57 million in grants to more than 250 scientists and clinicians at leading medical and academic institutions across 14 countries, making BCRF the largest private funder of breast cancer research in the world. We are tackling breast cancer on all fronts by funding research across the entire spectrum of the disease, including:

• Uncovering the very roots of cancer by studying tumor biology
• Understanding the role of genetic susceptibility
• Reducing breast cancer risk through lifestyle and prevention strategies
• Developing targeted treatments to outsmart cancer
• Improving quality of life during and after treatment
• Unravelling the mystery of metastasis

With the scientific freedom provided by BCRF funding, well over half a billion dollars has fueled innovations and novel approaches to discovery. Investing in research produces tangible results—there are 3.5 million breast cancer survivors in the country today. The number of deaths have dropped by 30 percent over the last 20 years. Progress is undeniable, but more needs to be done. With no known cure, more than 40,000 Americans will die this year from metastatic breast cancer. BCRF is confident that lifesaving discoveries lie in wait. Led by the vision of an esteemed board of directors comprised of trailblazers in business, media, and philanthropy, alongside a scientific advisory board with the best minds in science, we are closer than ever to fulfilling our mission: to be the end of breast cancer.

Sincerely,

Myra J. Biblowit
President and CEO

Kinga Lampert
Co-Chairman

William P. Lauder
Co-Chairman
When BCRF was founded, a breast cancer diagnosis invoked fear and little hope. Scientific understanding of the nature of the disease and how it moved through the body was still nascent. Investigations on prevention strategies were new, screening methods were limited and treatment options were few.

The scientific community has discovered more about breast cancer, and all cancers, in the past two decades than it has in the last 100 years.

Since 1990, after remaining stagnant for more than 50 years, the rate of deaths due to breast cancer has declined by more than 30 percent; and five-year survival rates of breast cancer are better than 90 percent when detected and treated early. We are moving beyond a “one-size-fits-all” approach to treatment with the development of targeted, more effective therapies for patients. Advances in treatment and early detection are why there are more than 3.5 million women with a history of breast cancer alive in the U.S. today.

These milestones are the results of research. Research is revolutionizing our understanding of cancer. Research is leading us to the core of this insidious disease. Research is bringing an end to cancer as we know it.

When Evelyn Lauder and Dr. Larry Norton, BCRF’s Scientific Director, created BCRF more than 20 years ago, they realized the irrefutable power of research. They saw its potential to unlock the complexities of cancer and change the lives of millions of women and men worldwide.

Mrs. Lauder and Dr. Norton grounded their vision in an innovative grant-making process that values freedom, creativity and collaboration just as much as rigor and accountability. Nearly 25 years later, BCRF is as committed as ever to not only helping the most brilliant minds in science and medicine pursue big-impact ideas, but also moving those ideas from the lab to the patient as quickly as possible.
When BCRF was formed there was little understanding of the nature of breast cancer and how it moved through the body. The support from BCRF’s dedicated community — our donors, partners, researchers and all those affected by the disease — has changed that.

This year BCRF is investing $57 million in research and supporting more than 250 investigators across 14 countries, making us the largest private funder of breast cancer research in the world. We must maintain the momentum of accelerating advances to improve the lives of those affected by this disease. The need is urgent; every moment spent in the lab is a moment closer to finding a cure.
From the beginning, BCRF has sought the most brilliant researchers to unravel the complexities of cancer. We fund people – not projects – and it is because of them that BCRF is a longstanding leader in breast cancer research.

Our Scientific Advisory Board (SAB) directs BCRF’s research efforts by seeking out the promise and potential in individuals around the world who can bring us closer to the end of cancer. Each year, BCRF’s Scientific Advisors invite proposals from pioneering laboratory scientists and clinical investigators making headway in cancer research. After careful deliberation and an assessment of the most promising leads, the SAB awards grants once a year.

“It is clear that we have made significant progress toward eradicating breast cancer and while there is much more to be accomplished, the pace toward that goal is rapid and accelerating,” said Dr. Larry Norton, BCRF Scientific Director. “BCRF’s approach—attacking breast cancer from all angles and giving brilliant investigators freedom and collegial spirit to rise to their best work—has provided great impetus and offers tremendous hope.”

With each grant awarded, BCRF’s scientific leaders demonstrate trust in the distinguished investigators to collaborate, pursue creative ideas and explore promising breakthroughs. Our areas of focus span the spectrum of breast cancer research including tumor biology, heredity and ethnicity, lifestyle and prevention, treatments, survivorship, and metastasis—tackling breast cancer on all fronts.

“One of BCRF’s defining characteristics is its willingness to take risks by giving scientists the freedom to be innovative, daring and original,” said Dr. Judy Garber, Chairman of BCRF’s Scientific Advisory Board. “We don’t expect everything to work, but we do expect there to be real advances in science. Our reward is in lives saved.”

**BCRF Scientific Advisory Board**

**Larry Norton, MD**  
*Scientific Director*  
Memorial Sloan Kettering Cancer Center

**Judy E. Garber, MD, MPH**  
*Chairman*  
Dana-Farber Cancer Institute  
Harvard Medical School

**Joan S. Brugge, PhD**  
Harvard Medical School

**Nancy E. Davidson, MD**  
Fred Hutchinson Cancer Research Center, University of Washington

**Susan M. Domchek, MD**  
University of Pennsylvania

**Patricia A. Ganz, MD**  
University of California, Los Angeles

**Peter Greenwald, MD, DrPH**  
National Cancer Institute  
National Institutes of Health

**Gabriel N. Hortobagyi, MD, FACP**  
MD Anderson Cancer Center, University of Texas

**Martine J. Piccart-Gebhart, MD, PhD**  
Institut Jules Bordet

**Lajos Pusztai, MD, DPhil**  
Yale University School of Medicine

**Vered Stearns, MD**  
Johns Hopkins School of Medicine
THE ROOTS OF CANCER: TUMOR BIOLOGY

Research on the biology of cancer starts with the simplest of questions: What is—and isn’t—a normal cell? How does a normal cell become cancerous? Why does it grow out of control to form a tumor and spread, a process known as metastasis, to other parts of the body?

Thanks to the groundbreaking work of Dr. Charles Perou and colleagues, we now know that breast cancer is, in fact, several diseases, each of which develops, progresses and responds to therapies differently.

Research Highlights
Our investigators are exploring the unique characteristics of cancer cells, how and why they transform from normal to abnormal and what drives a tumor’s response to any particular treatment. Because of groundbreaking research, we are learning that breast cancers share commonalities with cancers arising in other organs.

Some BCRF investigators are looking within cells [at DNA, RNA, and proteins] to gain a deeper understanding of what makes a cancer cell. For example, Dr. Lewis Chodosh and others are working to identify specific genes and pathways by which breast cancer recurs to develop targeted therapies.

Investigators have also focused on interactions outside of the cell. In addition to pioneering the use of 3D culture models that replicate breast tumors, Dr. Mina Bissel and others are studying the interactions of the tumor cell and its surrounding environment to identify signals of metastasis and targets for therapy.

Simultaneously, several BCRF investigators have taken a step back to study the various cells that make up a tumor. Work by Drs. Kornelia Polyak, Charles Swanton and colleagues have shown that each breast tumor can contain several types of cancer cells. This might be why current therapies do not work for some patients and why novel approaches are being developed to deal with such complexity.

Understanding the basic biology of breast cancer is allowing us to get to the very core of the disease. Every aspect, from a cancer cell’s genes to the tumor’s environment, is under investigation. BCRF scientists are giving us the knowledge to achieve prevention, develop new treatments and a cure.

IN 2016, BCRF IS INVESTING $10 MILLION IN TUMOR BIOLOGY FUNDING 44 PROJECTS
UNDERSTANDING RISK FACTORS: GENETICS, HEREDITY & ETHNICITY

A person’s family history, gender, age, race and ethnicity are all important risk factors for breast cancer. BCRF-funded research is improving our understanding of inherited gene mutations, developing low-cost genetic testing and developing targeted treatments for inherited cancers. Studies include prevention and early detection, the basic biology of BRCA-related breast and ovarian cancers, development and testing of novel therapies, identifying biomarkers of resistance to targeted therapies, racial disparities and clinical trials.

INHERITED RISK
About 5 to 10 percent of breast cancers are thought to be caused by inherited genetic mutations.

BCRF-funded scientists Drs. Mary-Claire King at the University of Washington and Alan Ashworth at the University of California, San Francisco greatly advanced the field of hereditary breast cancer with their discoveries of the breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2. Other BCRF-funded scientists have discovered additional genetic links to aggressive breast cancers in Latin American and African American populations. Mutations in BRCA1 and BRCA2 have also been associated with a number of other cancers.

Research Highlights
Drs. Fergus Couch, Katherine Nathanson and Kenneth Offit are studying the genome of over 21,000 patients with breast cancer and BRCA1 mutations, as well as over 4,000 with triple-negative breast cancer, to create a more personalized approach to risk assessment.

RACE AND ETHNICITY
Although we know that mutations in certain genes increase a person’s chances of developing breast cancer, race and ethnicity are also important in understanding the development and aggressiveness of the disease.

Research Highlights
BCRF grantee Dr. Christine Ambrosone is currently studying racial differences at the DNA level to increase our understanding of breast cancer biology, particularly for more aggressive triple negative breast cancers, which occur more frequently in African Americans compared to Caucasians.

INTERNATIONAL MEDICINE
BCRF investigators are studying the disease internationally to improve breast cancer care in regions with limited access to healthcare.

Research Highlights
Drs. Ephrat Levy-Lehad, Mary-Claire King and Moien Kanaan are studying the frequency of BRCA1 and BRCA2 mutations in Palestinian Arabs and non-Ashkenazi Jewish populations in Israel and the Middle East. Eleven new genetic mutations, in addition to BRCA1 and BRCA2 mutations, have been identified to date.

Identifying high-risk individuals is key to preventing breast cancer, and one way of doing so is to identify people with inherited mutations that increase their breast cancer risk. These risks may run in families, where frequent cancers occur, especially early in life, or across ethnicities, such as BRCA mutation in people of Ashkenazi Jewish ancestry.

Dr. Jeffrey Weitzel’s work in Latin America and Mexico is helping to create an infrastructure of genetic counselors and to develop low-cost genetic testing tools to apply in their home countries. Due to the lack of available genetic testing, we are only just beginning to learn about the level of inherited risk in Latin American populations.

Similarly, Dr. Funmi Olopade has made significant strides in Southwest Nigeria and Sub-Saharan countries. The project has identified major barriers to breast cancer care in Nigeria and is working on a variety of ways to address those barriers and improve access to care and train local clinicians.

IN 2016, BCRF IS INVESTING $5 MILLION IN HEREDITY & ETHNICITY RESEARCH FUNDING 13 PROJECTS
REDUCING RISK: LIFESTYLE & PREVENTION

Each year 250,000 women and 2,000 men are diagnosed with breast cancer. Only about 10 percent of all breast cancer cases are caused by inherited genes (such as mutations in BRCA1, BRCA2 genes). So while the underlying causes of breast cancer are poorly understood, lifestyle and environment are key factors influencing cancer risk. Experts estimate that up to one half of cancer cases can be prevented through lifestyle choices and risk-reduction strategies. The same recommendations for prevention of heart disease, hypertension and diabetes (maintaining a healthy weight and regular exercise) may also reduce the risk of breast cancer.

LIFESTYLE INTERVENTIONS
It is never too late to make lifestyle changes. BCRF-funded research has shown that weight loss at any age significantly lowers breast cancer risk factors such as those controlling the blood vessels that support tumor growth.

Research Highlights
Dr. Graham Colditz is studying how early life exposures affect normal adolescent growth and how these changes influence adult risk of breast cancer.

Drs. Walter Willet, Melinda Irwin and Ann McTiernan are examining how diet and exercise influence breast cancer risk and outcomes.

Drs. Andrew Dannenberg and Neil Iyengar are investigating the molecular changes induced by obesity to promote breast cancer development, progression and metastasis and develop new strategies to identify those at risk and effective interventions.

REDUCING THE RISK OF RECURRENTNESS
The five-year survival rate for early stage breast cancer (Stage 0-1) is nearly 100 percent. However, late recurrence—that is 10, 15 and even 20 years after initial diagnosis and treatment—remains a serious clinical concern. Understanding tumor biology is key to predicting those at high-risk of recurrence. For many high-risk women, chemoprevention with anti-estrogen therapies can dramatically reduce the risk of recurrence. Understanding which groups are at highest risk and ensuring access to screening and appropriate genetic counseling are key prevention strategies in this population.

Research Highlights
BCRF is supporting studies aimed at preventing recurrence by:
• Testing novel approaches to improve risk stratification for both women with and without breast cancer.
• Developing promising interventions for breast cancer prevention using biomarkers in blood or in normal breast tissue.
• Conducting clinical trials in chemoprevention in high-risk women.
• Understanding the frequency of BRCA 1/2 mutations in women of Ashkenazi Jewish descent without a family history of breast cancer.
OUTSMARTING CANCER: NEW TREATMENT APPROACHES

It is important to know that breast cancer is not just one disease. There are many different types of breast cancer that may present differently and have different treatments. The most common type of breast cancer is invasive ductal carcinoma. Invasive ductal carcinoma can be further classified into several subcategories, including:

• "Hormone sensitive," or cancers fueled by the hormones estrogen and progesterone (ER/PR positive).
• "HER2+ positive," or cancers driven by the HER2 gene.
• "Triple negative," or cancers with none of the three markers (do not express ER, PR or HER2).

Targeted therapies are available for breast cancers that are driven by hormone receptors or HER2, but for many breast cancers, including triple negative breast cancer, targeted therapies have not yet been approved in the U.S.

Other types of breast cancer include invasive lobular carcinoma, inflammatory breast cancer, Paget disease of the nipple, and Phyllodes tumors which are less common and less studied types of breast cancer.

While significant progress has been made in developing new treatments for breast cancer over the last 25 years, much work remains. There is an urgent need for new treatments for people diagnosed with metastatic breast cancer (MBC), triple negative breast cancer, or breast cancers that are or have become resistant to available drugs.

Research Highlights

Immunotherapy is a promising new area of research but thorough study of the immune system and immune modulating drugs is needed. BCRF is investing $6.5 million this year into immune studies in breast cancer and immunotherapies.

• Cancer vaccines are designed to stimulate the immune system to fight cancer and provide "immune memory" to fight future cancer cells. Drs. Leisha Emens and Elizabeth Jaffee are testing a novel vaccine for breast cancer using intratumoral injection of an immune stimulant as a personalized vaccine.
• Immune Checkpoint Therapy: Immune checkpoint inhibitors (PD-L1/PD1 pathway) have shown great promise in cancer therapy. Drs. Lajos Pusztai and David Rimm have designed and lead the first clinical trials that test these agents in early stage triple negative breast cancer. They are also developing tests that will predict a cancer's response to immune therapy drugs.
• Adoptive T-Cell Therapy: Anti-tumor immunity can be enhanced by a method called adoptive T-cell therapy, in which T-cells are obtained from patient blood, grown outside the body, tested to make sure that they recognize the patient’s cancer, and then infused back into the patient. Dr. Mary (Nora) Disis has developed a method to "supercharge" these T-cells against the cancer by making them secrete many different immune system molecules that help kill cancer, making them "polyfunctional."

A class of drugs called CDK4/6 inhibitors, examples include palbociclib, abemaciclib and ribociclib, are generating much excitement as new therapeutic approaches in advanced ER/PR-positive breast cancers. As part of the Drug Research Collaborative, palbociclib was made available to BCRF investigators and is being studied in three of the six laboratory studies.

DRUG RESEARCH COLLABORATIVE

In 2016, BCRF launched the Drug Research Collaborative, an unprecedented new funding model aimed at bridging the gap between academic investigators and new drugs in development. BCRF has announced nine new projects that are part of this ground-breaking collaboration between BCRF, Pfizer and the Translational Breast Cancer Research Consortium (TBCRC). This program will be funded with an initial $15 million commitment from Pfizer along with newly available access to Pfizer’s broad portfolio of approved products and its pipeline of 16 oncology drugs still under development. The collaborative will support clinical trials that will be conducted and managed by the TBCRC. The three trials selected will test drugs under development for immunotherapy, cell cycle inhibition and kinase inhibition. Nearly 400 patients will be involved. Laboratory studies will advance our understanding of mechanisms of action of drugs, drug combinations and how to overcome resistance to current therapies.
Metastatic breast cancer occurs when breast cancer cells spread to other parts of the body, for instance the lungs, liver, brain or bones and form new tumors there. Metastatic breast cancer (MBC), sometimes referred to as stage IV or advanced breast cancer, is responsible for virtually all breast cancer-related deaths.

To metastasize, cancer cells have to leave the breast and get into the circulation, usually in the bloodstream or lymphatic system. Next, cancer cells must find their way to another organ, enter the new organ, survive in that new environment and learn how to grow and divide uncontrollably in their new setting.

**Research Highlights**

Developing better treatments requires an understanding of all the processes of metastasis. In 2016, BCRF committed nearly 30 percent of its $57 million grant-making program to metastasis research. Projects span the spectrum of the cancer process to identify both early and late events that lead a cancer cell to become metastatic. BCRF investigators are using this information to devise ways to prevent metastasis from occurring and developing better treatments for late stage disease. They are developing model systems to accurately mimic the disease, studying tumor biopsies for the identification of biomarkers that can predict drug response or resistance, and conducting well-designed clinical trials.

Dr. Sofia Merajver, BCRF investigator since 2004, is testing simple synthetic devices that mimic human organs. By placing live cancer cells from breast cancer patients inside the devices, Dr. Merajver’s team can study which cells are able to spread to distant sites, even before a tumor would be clinically detectable. These small inexpensive devices could dramatically improve breast cancer surveillance in remote areas and low resources settings.

Groundbreaking work by Dr. Kornelia Polyak, BCRF investigator since 2008, demonstrated the diversity of cells within a tumor and led the way for the study of tumor heterogeneity and advanced our understanding of the unique biology of cancer cells that spread from the breast compared to those that don’t.

Dr. Fabrice André, BCRF investigator since 2011 and his international colleagues are exploring this landscape to identify mutations in metastatic disease that could help explain drug resistance and lead to better treatments.

**In 2016, BCRF is investing $16 million in metastatic breast cancer research, funding 20 projects**

**How Cancer Spreads: Metastatic Breast Cancer**

- Nearly 100% of breast cancer deaths are due to metastatic breast cancer.
- Nearly 100% of early stage patients experience a recurrence and develop metastasis.
- Up to 30% of early stage patients experience a recurrence and develop metastasis.
- More than 400,000 American women and men die from breast cancer each year.

**Metastatic Breast Cancer Alliance**

Critical data on metastatic breast cancer are missing: it is unknown how many people are living with metastatic disease today, how many early stage patients experience a recurrence, or how long women and men live after receiving a diagnosis of MBC. The Metastatic Breast Cancer Alliance (the Alliance) was formed in 2013 to address these and other urgent questions about MBC. Since 2015, BCRF has served as the administrative home of the Alliance and provides staff to serve the Alliance’s mission and to advance Alliance projects. BCRF staff are actively involved in solving unanswered questions in “MBC epidemiology” as well as exploring how to accelerate MBC research cooperatively with other Alliance members.
Advances in early detection and treatment have largely contributed to a decline in deaths due to breast cancer over the past two decades. With more than 3.5 million breast cancer survivors in the U.S., the largest cancer survivorship group in the country, addressing the physical, mental and emotional challenges faced by patients has become all the more important.

Just as breast cancer is a very heterogeneous disease, those diagnosed with breast cancer are a diverse group of people. Life after breast cancer is a unique experience for each woman or man and is influenced by many factors. The goal of breast cancer treatment is to extend the lives of patients, but those life-saving treatments can have prolonged physical and emotional effects. Treatment-induced symptoms such as peripheral neuropathy (pain or numbness in the fingers or feet), lymphedema (build-up of lymph fluid under the skin causing uncomfortable swelling in the arms and hands), sexual dysfunction (such as vaginal dryness and loss of libido) and cognitive impairment (sometimes called chemo brain) can persist long after the treatment has ended. Because those affected by breast cancer are living longer, managing the long-term side effects of treatment is important to the quality of life during those extended years.

Research Highlights
With BCRF support, researchers are working to personalize care and better predict and manage side effects, to not only increase lifespan with more effective therapies, but improve the quality of life for patients during and after treatment.

Drs. Debra Barton, Charles Loprinzi and Carol Fabian are investigating sexual health after breast cancer, including understanding how vaginal symptoms, fatigue, body image, and partner issues predict overall sexual health. They are also studying interventions for body image issues and testing non-estrogenic agents for the management of hot flashes.

BCRF Scientific Advisory Board Member and grantee Dr. Patricia Ganz seeks to understand how certain breast cancer treatments may accelerate the development of age-related cognitive decline.

Drs. Melinda Irwin and Elektra Paskett are investigating the role of diet, exercise, medication adherence and body weight on breast cancer and survivorship issues in women at high risk for breast cancer. They will also develop and test innovative biomedical and behavioral interventions for preventing breast cancer recurrence.
SUPPORT FROM COAST TO COAST

Delta Breast Cancer One Flight: NYC to LA

Independent Fundraiser: West Dover, VT

Boston, MA

Palm Beach, FL

Hamptons, NY

Women's Cancer Research Fund: Los Angeles, CA

Long Island, NY

The Pink Agenda: New York, NY

Play for P.I.N.K.: Boyton Beach, FL
BCRF is honored to have such committed supporters around the world. Whether they contribute by attending a BCRF signature event, participating in an independent fundraiser or simply sharing our mission on social media, our community drives our ability to successfully fund research.

BCRF events raised over $16.6 million last year—funding 67 research grants. With the help of our dedicated supporters, BCRF’s footprint has indelibly marked the country from coast to coast with signature and regional events spreading across Boston, Hamptons, Westchester, Long Island and New York City, to Palm Beach, FL and Los Angeles, CA.

In 2016, the Women’s Cancer Research Fund (WCRF) joined forces with BCRF to go even further in its ability to fast-track more effective approaches to the study and early diagnosis of women’s cancers, with initial grants supporting funding in three areas of research: tumor biology and pathology, treatment for triple negative breast cancer, and developing model systems to better understand cancer behavior and metastasis.

Longtime partner Play for P.I.N.K. (PFP), a volunteer-driven organization that donates 100% of its proceeds to BCRF, once again successfully harnessed the power of volunteers across the country. In 2016, over 30,000 participants nationwide supported PFP through various sporting and lifestyle events raising $4.8 million for research.

The Pink Agenda (TPA) is an organization comprised of young professionals dedicated to funding breast cancer research in partnership with BCRF. In 2016, TPA’s millennial donor base raised nearly $650,000 via campaigns and events in New York, Atlanta, Boston and D.C. In collaboration with Giuliana Rancic’s FAB-U-WISH, TPA also grants wishes for young women currently undergoing treatment for breast cancer.

Volunteers and donors are working tirelessly to fund more research each and every day in a variety of ways. Independent fundraisers—both large and small—have contributed more than $4.4 million this year alone towards our shared vision of a world free of breast cancer.
Engaging with the private sector has been a core tenet of BCRF since it was founded by Evelyn Lauder alongside The Estée Lauder Companies’ Breast Cancer Awareness Campaign. Since 1993, partners have funded $297.5 million in research. Considered the gold standard in cause marketing by the New York State Attorney General’s Office, BCRF’s partnerships are authentically making an impact by harnessing the power of consumers, companies and the communities they reach.

“BCRF’s focus on research was really compelling for us. We like being able to show our community the measurable impact of their donations in the spirit of transparency.”

– Steven Izen, Founder and CEO, Lokai
THE POWER OF PHILANTHROPY

We are grateful to the following donors for their generous support during the year ended June 30, 2016:

**Donors of $3,000,000 or more**
- ANR INC., a division of ascena retail group inc.
- The Estée Lauder Companies Inc.
- Pfizer Inc.
- Play For P.I.N.K.
- Ultra Beauty

**Donors of $1,000,000–$2,999,999**
- AutoNation, Inc.
- Bloomberg Philanthropies
- Bloomingdale’s, Inc.
- CareOne Charitable Fund
- Gwendolyn and Joseph Straus
- Delta Air Lines
- Estée Lauder
- Housewares Charity Foundation
- J.C. Penney Corporation, Inc.
- The Lauder Foundation–Leonard & Judy Lauder Fund
- Macy’s, Inc.
- Smart Circle/RGS Labs
- International, Inc.
- Women’s Cancer Research Fund
- The Wright Foundation Inc.

**Donors of $500,000–$999,999**
- Cindy and Rob Citrone
- Clinique
- Estée Lauder Field Force
- North America
- Estée Lauder New York
- Area Employees
- Karen and Rob Hale
- Kinga Lampert
- Medical Research Charities/Neighbor to Nation
- Tanger Factory Outlets
- Joseph and Arlene Taub Foundation
- Wilson Sporting Goods Co.

**Donors of $250,000–$499,999**
- A Cure in Our Lifetime
- Alex and Ani
- Ascend Hospice
- Aveda
- Avon Foundation
- Tory Burch

**Donors of $100,000–$249,999**
- Susan and Richard Anderson
- Apollo Tools, Ltd.
- Armaly® Brands
- Jody and John Arnhold
- BirchBox
- Bobbi Brown
- Bunco for Breast Cancer
- Catherines, a division of ascena retail group inc.
- Celebrity Cruises
- Lisa Pevaroff-Cohn and Gary Cohn
- Conair Corporation
- Condé Nast
- D’Arrigo Bros. Co. of California
- David Yurman
- Dillard’s Inc.
- Eli Lilly and Company
- Estée Lauder Field - East Coast
- Estée Lauder London Affiliate
- Everlast Worldwide, Inc.
- Firmenich
- Estate of Deborah A. Cain Fletcher
- Amy Goldman Fowler
- Goldman Sachs Gives
- The Horace W. Goldsmith Foundation
- Neil and Jane Golub Family Foundation
- Hearst Corporation
- Holiday House
- Jo-Ann Fabric and Craft Stores
- Jo Malone
- William P. Lauder
- Samuel I. Newhouse Foundation Inc.
- Novartis Oncology
- Orlando Sports Foundation
- UCF ED
- Ralph Lauren
- Lily Safra
- The Salon People/Aveda
- Jeanne and Herbert Siegel
- Spring Meadow Nursery, Inc./Proven Winners® ColorChoice® Shrub
- Stage Stores
- Suffolk Construction Company
- Superior Plus Energy Services/Griffith Energy
- The Tijuana Flats Just in Queso Foundation
- Tommy Cares and PVH Foundation

**Donors of $50,000–$99,999**
- Aramis & Designer Fragrances
- AstraZeneca
- Anne H. Bass
- Bee Sweet Citrus
- BNY Mellon
- Brooks Brothers
- Bumble and bumble.
- C.O. Bigelow Apothecaries
- CAROLEE
- Jim and Marilyn Simons
- The Fred B. Snite Foundation
- Donna and James Stearns
- Strategic Distribution, L.P.
- Streamlight, Inc.
- SWK 1974 Trust
- Target Corporation/Sonia Kashuk
- Time Inc.
- Tom Ford Beauty
- Tory Burch, LLC
- Tough Enough to Wear Pink
- Toys “R” Us, Inc.
- Traders4ACause
- Tupperware Nordic A/S
- TYR Sport, Inc.
Nina and Gary Wexler  
World Class Salons

**Donors of $25,000–$49,999**

ACCO Brands USA, LLC  
Alaska Run for Women  
Almira Family Foundation  
Robert A. Amon  
ascena retail group inc.  
Maria and Larry Baum  
Joan and Robert Blackman  
Bland Farms LLC.  
Stuart Boesky  
The Bon-Ton Stores, Inc.  
Benjamin Bram  
Irma Braman  
Louise and David Braver  
Philanthropic Fund  
Andrew and Erik Brooks  
Shelly and Larry Brown  
Bunco for Breast Cancer, Westmont, IL  
Susan and Alan Bushell/Tour De Bondville  
Cabeau  
CafePress.com  
California Costumes  
Caribbean Wonders  
Carpet One Floor & Home  
Carpe Diem  
Carpe LA  
Catherine Adams/Teddy Bears to the Rescue  
Advanta Medicaid LLC  
American Express  
After Hours  
Arkay Packaging  
Blue Ridge Orthodontics  
Bosley Medical  
Clarissa and Edgar Bronfman, Jr.  
Coach Watches  
Cocktails for the Cure  
Crawley for Cancer Inc.  
Dana-Farber Cancer Institute  
Donna Karan  
The Ellen DeGeneres Show  
Delta Sonic Car Wash Systems, Inc.  
Michele Docharty and Eric Linder  
Douglas Elliman/Dottie Herman and Howard Lorber  
dressbarn, a division of ascena retail group inc.  
Elburn Bunco for Breast Cancer (BFBC)  
Elite Business Productions  
Janice Ellig  
Empire Blue Cross Blue Shield  
Ernst & Young LLP  
ESCAPA US  
Estée Lauder - Belgium Affiliate  
Estée Lauder - Kabushiki Kaisha  
Andrew L. Farkas  
Fashion Group  
Find a Cure RX Card  
First Republic Bank  
For Eyes Optical  
Lisa and Tomas Friedlander  
Anne Marie Giardino  
Genomic Health  
Givaudan  
Marjorie and Josh Harris  
Tommy and Dee Hilfiger  
Todd Hitt and Michelle Dolansky  
The Hunt Family Charitable Fund  
International Flavors & Fragrances, Inc.  
Ivy Ella LLC  
JD Beauty Group  
Joerns Healthcare  
Wayne and Shelly Jones  
K & L Gates LLP  
K-2 Sports  
Sinesia and Bill Karol  
Nancy and Rick Kelleher  
The Kelly Cares Foundation  
Kodiak Computer Services  
Koi Design LLC.  
Sandra G. Krakoff  
La Tortilla Factory  
Lab Series  
Elyse Lacher  
Laura and Steve Lang  
Jo Carole and Ronald S. Lauder  
Laura and Gary Lauder  
Peta and Stephen Levin  
Linda and Steven Levy  
Lowenstein Sandler LLP  
The Lynch Foundation  
John and Linda MacDonald Foundation  
MacroGenics, Inc.  
James R. Malek  
MANA  
Manic Panic® NYC  
Manion Gaynor & Manning LLP  
The McCance Foundation Trust  
Kristen and Patrick McMahon  
Memorial Sloan Kettering Cancer Center  
Harold Michaels, Esq.  
Mobilex  
Modell’s Sporting Goods  
The Ambrose Monell Foundation  
Monello Landscape LLC  
Morgan Stanley  
NEST Fragrances  
New York - Presbyterian Hospital  
The New York Times  
Ogletree, Deakins, Nash, Smoak & Stewart, P.C.  
Origins  
Liliane and the late Norman Peck  
PepsiCo Foods  
Kitty and Tim Pinch  
Polo Ralph Lauren Foundation  
Pink Pony Fund  
Popular  

The Presto Foundation  
Professional Bull Riders, LLC  
Patricia Quick  
Theodore A. Rapp Foundation  
Andrea Redmond and William Ferguson  
Lynda and Stewart Resnick  
Wendi Rose/Marshall Rose Family Foundation  
Pat and John Rosenwald  
Rue La La  
Pheodora and Myung Shin  
Edna Shostak  
Jackie and Bippy Siegal  
Smith Family Foundation  
Spectrum Brands, Inc.  
Stampin’ Up! Inc.  
Christina and Hal Steinbrenner  
Carl Stiewe  
Daniel and Brett Sundheim  
Susanne’s Friends/Susanne Fischer  
Teleflora LLC  
TFT Wheeling/Chantelle Kern  
Lizzie and Jonathan Tisch  
US Foods  
W.B. Mason  
The Walsky Family Foundation  
Wishes by Wyndham Foundation  
YourCause LLC

**Donors of $15,000–$24,999**

Catherine Adams/Teddy Bears to the Rescue  
ADF Field  
Advanta Medicaid LLC  
American Express  
Tracy Anderson  
Apple and Eve, LLC  
Arkay Packaging  
Beauvoir Swoozies LLC  
Lloyd and Laura Blankfein  
Emily and Leonard Blavatnik  
Blue Oak Charitable Fund  
Blue Ridge Orthodontics  
Bosley Medical  
Clarissa and Edgar Bronfman, Jr.  
Rita and Charles Bronfman  
Buchanan Ingersoll & Rooney PC  
Mrs. John J. Byrne  
Carpet One Floor & Home  
Lois Chiles and Richard Gilder  
Chino Basque Club  
Chopin Imports Ltd.  
Clove Run Country Club Women’s Golf Leagues/Connie U. Williams  
Coach Watches  
Cocktails for the Cure  
The Corner Stop  
Crawl For Cancer Inc.  
Dana-Farber Cancer Institute  
Ellen and Gary Davis Foundation
Donors of $15,000–$24,999 (continued)

Delta Clipped Wings, Inc.
Timothy Dent
Dickinson + Associates
Estate of Carol M. Dietrich
Edmonds Contracting, Inc.
Katherine Farley
and Jerry I. Speyer
For the Girls, Inc.
Bill Ford and Marigay McKee
FoxRock Properties
Samuel J. and Connie M.
Frankino Foundation
Paul Fribourg/Continental
Grain Company
Give With Liberty Employee Donations
Gold Canyon International, LLC.
Valerie and Gregory Gorder
Grandeur Peak Global Advisors, LLC
Hackensack University Medical Center
Alexandra Herzan
Jelly Belly Candy Company
Kekst and Company
Timothy C. Kerr Family Foundation
Stacie and Stephan Kiratsous
Sheila Lambert
The Eleanor F. Langan Foundation of 1997
Estate of Claire T. Lecas
Levittown Soccer Club/Pelini Fund
The Lucille Roberts National Foundation for Women, Inc.
Nancy and Howard Marks
Massachusetts General Hospital Cancer Center
Blythe Masters and Gareth Evans
Mary Bryant McCourt
McDermott Will & Emery
McKesson Medical-Surgical, Inc.
Meadows Farms
Megabus North East LLC
Mercer (US) Inc.
New York Football Giants Foundation, Inc.
The New York Racing Association, Inc.
Nordstrom
Jane and Daniel Och
Officemate International Corporation
Christiane Olsen
Ouidad, Inc.
Paint the Porch Pink
Cynthia Polsky/Lita Annenberg
Hazen Foundation
John Rallis
The Bruce Robert Reid Family Foundation
The Rim Golf Club
Rolex Watch USA
R-Pharm US LLC
Judith P. and S. Lawrence Schlager
Seminole Casino Coconut Creek
Carl & Ruth Shapiro Family Foundation
The Muriel F. Siebert Foundation, Inc.
David E. and Jacqueline S. Simon Charitable Foundation
Laura and Harry Slatkin
SmartLinx Solutions LLC
Smashbox Beauty Cosmetics
Barry S. Sternlicht/Starwood Capital Group
Sunstar Americas, Inc
Henry and Marilyn Taub Foundation
TCL North America Teespring Inc.
David Thieme
Jamie Alexander Tisch
Trudeau Corporation
True Religion Brand Jeans
Maria Hummer-Tuttle and Robert Tuttle
The United States Playing Card Company
Violet Flower Shop
Volkswagen Golf Outing
W.R. Berkley Corporation
The Walrath Family Foundation
Vera Wang
Hollie Watman
Weil, Gotshal & Manges
J. Weinstein Foundation Inc.
Westreich Finaly Foundation, Inc.
Rita Wilson and Tom Hanks
Amy Winebright
Winston Flowers - Charity In Bloom
Carol Yermal
Lee R. Zeidman
Donors of $10,000–$14,999
21st Century Fox
Bill Ackman
Drs. Hugh Allen and Julie Gralow
Stephanie Andrews and Marc White
Aramis Field
Archer & Greiner
Attic Needlework & Collectibles
Debbie and Glenn August
Barneys New York
Bill Belichick and Linda Holiday
Stuart and Susan Bell
Family Foundation
Benefit Management Solutions Inc.
Juliet and Joshua Berkowitz
Michael and Marcela Berland
Berne Apparel
Beth Israel Deaconess Medical Center
Myra and Charles Biblowit
Jane Sudler Black
Pamela Blalock
Mary-Ann and Fabrizio Freda
Fun Raisers Foundation, Inc.
G & C Auto Body, Inc. Corporate Gaiam Americas, Inc.
The Gap, Inc.
Johanna and Leslie Garfield
The Dolores & Donald Burnett Foundation
California Pear Advisory Board
Cristina Carlino
Linda and Arthur Carter
Tip and Nino Catalano
Centurion Enterprises, LLC
CF Global Trading, LLC
Clean Facilities Group, Inc.
Richard & Martha Conway
Cool Gear International
Core Staffing Services Inc.
Jonathan Coslet and Jeanne Rosner
Custom Shootout
Henri Daussi
Ana Demel and Gary Stein
John D. Demsey
Designed for Health Care, Ltd
Charles and Valerie Diker
Kelly and Scott Donop/The Gold Coast Physical Therapy Golf Outing
Dooney & Bourke, Inc.
Robert Dow
Dyno LLC
Eagle Creek
Carol Ann Enquies
Englewood Hospital and Medical Center
Stephanie Ercegovic
Estée Lauder Dubai
Quinn and Bryan Ezralow
Raysa Fanjul
Joseph Feshbach
Cathy Franklin and Jeffrey Baker
Mary-Ann and Fabrizio Freda
Fun Raisers Foundation, Inc.
G & C Auto Body, Inc. Corporate
Gaiam Americas, Inc.
The Gap, Inc.
Johanna and Leslie Garfield
GCDC Marketing, Inc
The David Geffen Foundation

SUPPORT FROM COAST TO COAST
The Breast Cancer Research Foundation’s 2016 Major Donor List includes gifts received by the Foundation between July 1, 2015 through June 30, 2016. Every effort has been made to guarantee the accuracy of this list. Please contact us at 644-497-2612 or bcrf@bcrfcure.org if we have omitted your name or you wish to be listed differently in the future. Thank you for your support.
2016–2017 GRANTEES

ARIZONA
Arizona State University
Karen Anderson, MD, PhD
Joshua Laber, BS, PhD, MD
The Play for P.I.N.K. Award
University of Arizona
Jorge Gomez, MD, MS, PhD
University of Arizona College of Nursing
Usha Menon, PhD, RN, FAAN

CALIFORNIA
City of Hope
Arti Hurria, MD
The Delta Air Lines Award
Peter Lee, MD
on behalf of Stand Up to Cancer (SU2C)
Jeffrey N. Weitzel, MD
Cedars-Sinai Medical Center
Heather McArthur, MD, MPH
The Lokai Award, The Cynthia Lukin Award
Lawrence Berkeley National Laboratory
Mina J. Bissell, PhD
The Housewares Charity Foundation Award in Honor of Judy Colitz
Salk Institute for Biological Studies
Geoffrey M. Wahl, PhD
The Play for P.I.N.K. Award in Honor of Stacey Small and in Memory of Sheila Kasas Small
Stanford University
Michael F. Clarke, MD
The Hamptons Paddle & Party for Pink Award
Christina Curtis, PhD, MSc
The ULTA Beauty Award
James M. Ford, MD
The J.C. Penney Award
Mark Pegram, MD
George Stledge, MD
University of California, Irvine
Eva Y.-H. P. Lee, PhD
The ULTA Beauty Award
Wenqi Wang, PhD
American Association for Cancer Research
Clare Yu, PhD
on behalf of Stand Up To Cancer
University of California, Los Angeles
Julienne E. Bower, PhD
The Clinique Award
Tom Chou, PhD
Jayne Koskinas Ted Giavonis Foundation for Health and Policy Partnership
Steven W. Cole, PhD
The Clinique Award
Patricia A. Ganz, MD
The Estee Lauder Award
Annette L. Stanton, PhD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
University of California, San Diego
Alan Ashworth, PhD, FRS
Thomas J. Kipps, MD, PhD
The Macy’s Awards
Barbara A. Parker, MD
The Macy’s Awards
University of California, San Francisco
Alan Ashworth, PhD, FRS

Laura Esserman, MD, MBA
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
Deanna Kuroe, PhD
Hope S. Rugo, MD
Laura van ’t Veer, PhD
University of Southern California, Dornsife College of Letters, Arts and Science
James Hicks, PhD
The AutoNation Cure Bowl Award
Peter Kuhn, PhD
The AutoNation Cure Bowl Award
University of Southern California, Keck School of Medicine
David Agus, MD
The Women’s Cancer Research Fund Award
Paul Macklin, PhD, PhD
The Women’s Cancer Research Fund Award
Michael Press, MD, PhD
The Bloomingdale’s Award

COLORADO
University of Colorado Denver
Kathryn B. Horwitz, PhD
The Play for P.I.N.K. Award

CONNECTICUT
Yale School of Public Health
Melinda Irwin, PhD, MPH
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
Yale University School of Medicine
Christos Hatzis, PhD
The Play for P.I.N.K. Award
Lajos Pusztai, MD, DPhil
The Estee Lauder Companies Brands Award in Memory of Evelyn H. Lauder
DC
Institute of Medicine/ National Academy of Sciences
Sharly Nass, PhD
The Play for P.I.N.K. Award
Georgetown University Medical Center
Sandra Swain, MD
The ULTA Beauty Award

FLORIDA
Mayo Clinic Cancer Center (Jacksonville, FL)
E. Aubrey Thompson, PhD
The Play For P.I.N.K. Award
Moffitt Cancer Center
Heiko Enderling, PhD
Jayne Koskinas Ted Giavonis Foundation for Health and Policy Partnership
University of Central Florida
Annette R. Khaled, PhD
The AutoNation Cure Bowl Award
University of Miami
Tan A. Ince, MD, PhD
The Play for P.I.N.K. Award in Honor of Laura Lassman and in Memory of Nicholas Lassman
Marc E. Lippman, MD
The Bloomingdale’s Award

GEORGIA
Georgia Institute of Technology
Stanislav Emelianov, PhD
The Amy Robach Award

ILLINOIS
Loyola University Chicago
Kathy S. Albain, MD
The Housewares Charity Foundation Award
Claudia Osipo, PhD
The Housewares Charity Foundation Award
Northwestern University
William J. Gradishar, MD
The Housewares Charity Foundation Award
Seema A. Khan, MD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
University of Chicago
Yoo-Jeong Han, PhD
The ULTA Beauty Award
Olufunmilayo I. Olopade, MB, BS, FACP
The Estee Lauder Companies Brands Award in Memory of Evelyn H. Lauder, The ULTA Beauty Award
University of Illinois, Urbana-Champaign
John Katznellenbogen, PhD
The ULTA Beauty Award
Benita S. Katznellenbogen, PhD
The Play for P.I.N.K. Award

INDIANA
Indiana University School of Medicine
Kathy D. Miller, MD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
Anna Maria Sernstio, MD
The ULTA Beauty Award
Richard Zellars, MD
The Delta Air Lines Award

KANSAS
University of Kansas Medical Center
Carol J. Fabian, MD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.

MARYLAND
Johns Hopkins University Bloomberg School of Public Health
Kala Visvanathan, MBBS, FRACP, MHS
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
Johns Hopkins University School of Medicine
Leisha Emens, MD, PhD
Andrew Ewald, PhD
The Pink Agenda Award, Jayne Koskinas Ted Giavonis Foundation for Health and Policy Partnership
Daniei Gilkes, PhD
Jayne Koskinas Ted Giavonis Foundation for Health and Policy Partnership

Elizabeth Jaffee, MD
Ben Park, MD, PhD
The ULTA Beauty Award
Andrea Richardson, MD, PhD
The J.C. Penney Award
Dipali Sharma, PhD
Vedra Stearns, MD
The Estee Lauder Award
Antonio Wolf, MD
on behalf of EDR/IT/EMRC/BIIG/NABCG
National Institutes of Health
Peter Greenwald, MD, DrPH
University of Maryland
Fengtian Xue, PhD
American Association for Cancer Research
Walter Reed National Military Medical Center, John P. Murtha Cancer Center
Col. Craig Shriver, MD, FACS

MASSACHUSETTS
Beth Israel Deaconess Medical Center
Xiuning Le, MD, PhD
The Hirschhorn Award in Honor of Susan B. Hirschhorn and in Memory of Her Mother, Ellen S. Hirschhorn, Conquer Cancer Foundation of ASCO
Pier Paolo Pandolfi, MD, PhD
Stuart Schnitt, MD
The Housewares Charity Foundation Award
Nadine Tung, MD
The Housewares Charity Foundation Award
Gerburg Wulf, MD, PhD
Boston Children’s Hospital
Marsha Moses, PhD
The Clinicue Award
Zultan Saalasi, MD
Brigham and Women’s Hospital
Mehra Golshan, MD
The Hale Family Award
Brigham and Women’s Hospital/Harvard Medical School
Ross Berkowitz, MD
The Play for P.I.N.K. Award
Dana-Farber Cancer Institute
Myles Brown, MD
The Pink Promises Award in Memory of Patricia L. Hansen
Nancy Lin, MD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc.
Dana-Farber Cancer Institute/Harvard Medical School
Alan D’Andrea, MD
Ian Krop, MD, PhD
David Livingston, MD
Ursula Matulonis, MD
The Play for P.I.N.K. Award
Kornelia Polyak, MD, PhD
The ULTA Beauty Award
Eric Winer, MD
The ANN INC. Award, ANN INC. is a division of ascena retail group inc
Jean Zhao, PhD
The Hale Family Award
<table>
<thead>
<tr>
<th>2016–2017 GRANTEES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TENNESSEE</strong></td>
<td></td>
</tr>
</tbody>
</table>
| Vanderbilt University | Carlos L. Arteaga, MD  
| The Play for P.I.N.K. Award |  
| David Cortez, PhD  
| The Smart Circle/The RGS Labs |  
| Suzanne Fuqua, PhD |  
| The Play for P.I.N.K. Award |  
| C. Kent Osborne, MD  
| The Macy’s Award |  
| Rachel Schif, PhD  
| The Macy’s Award |  
| Xiang Zhang, PhD |  
| Houston Methodist Research Institute |  
| Jenny C. Chang, MD  
| The Estée Lauder Award |  
| Rice University |  
| Herbert Levine, PhD |  
| on behalf of Stand Up To Cancer |  
| University of Texas MD Anderson Cancer Center |  
| Michael Andreff, MD, PhD  
| The AutoNation Cure Bowl Award |  
| Powel Brown, MD, PhD |  
| The J.C. Penney Award |  
| Zhen Fan, MD |  
| The Story Half Told - Pfizer Oncology MBC Research Award |  
| Sharon Giordano, MD, MPH |  
| The Play for P.I.N.K. Award |  
| Gabriel Hortobagyi, MD, FACP, FASCO |  
| Mien-Chie Hung, PhD |  
| Gordon Mills, MD, PhD |  
| Sangheeta Reddy, MD, MSc |  
| Conquer Cancer Foundation of ASCO |  
| W. Fraser Symmans, MD |  
| The ULTA Beauty Award |  
| **TEXAS**            |  |
| Baylor College of Medicine |  
| Matthew Ellis, MB, BChir, PhD |  
| The Joan Lunden Award |  
| Suzanne Fuqua, PhD |  
| The Play for P.I.N.K. Award |  
| C. Kent Osborne, MD  
| The Macy’s Award |  
| Rachel Schif, PhD  
| The Macy’s Award |  
| University of Washington |  
| Mary Disis, MD |  
| The ULTA Beauty Award |  
| Julie Gralow, MD |  
| The Play for P.I.N.K. Award |  
| on behalf of SWOG |  
| Mary-Claire King, PhD |  
| The Roz and Les Goldstein Award |  
| Sasha Stanton, MD, PhD |  
| American Association for Cancer Research |  
| **WISCONSIN**       |  |
| University of Wisconsin |  
| Vincent L. Crins, MD |  
| The Housewares Charity Foundation Award |  
| **INTERNATIONAL**   |  |
| **ARGENTINA**       |  |
| Latin American and Caribbean Society of Medical Oncology (SLACOM) |  
| Eduardo Cazap, MD, PhD, FASCO |  
| **AUSTRALIA**       |  |
| University of Melbourne, Peter MacCallum Cancer Centre |  
| Sherene Loi, MD, PhD |  
| University of Newcastle |  
| John F Forbes, MB BS, FRACS, AM |  
| The Delta Air Lines Award |  
| on behalf of Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) |  
| **BELGIUM**         |  |
| Institut Jules Bordet |  
| Martine J. Piccart-Oeybrant, MD, PhD |  
| The Hamptons Paddle & Party for Pink Award |  
| on behalf of Breast International Group (BIG) |  
| Christos Sotiriou, MD, PhD |  
| **CANADA**          |  |
| Mount Sinai Hospital/University of Toronto |  
| Pamela J. Goodwin, MD, MSc, FRCP |  
| The Hudson’s Bay Company Award |  
| Ontario Institute for Cancer Research |  
| John Bartlett, PhD |  
| The Play for P.I.N.K. Award |  
| Queen’s University |  
| Leis E. Shepherd, MDCM, FRCP |  
| The ANN INC. Award, ANN INC. is a division of ascena retail group inc. |  
| **FRANCE**          |  |
| Institut Curie/Hospital Rene Huguenin |  
| Rosette Lidereau, PhD |  
| The Delta Air Lines Award |  
| Institut Gustave Roussy |  
| Fabrice André, MD, PhD |  
| The Estée Lauder Companies Brands Award in Memory of Evelyn H. Lauder |  
| **ISRAEL**          |  |
| Clalit National Israeli Cancer Control Center (NICCC) |  
| Gad Rennert, MD, PhD |  
| Shaare Zedek Medical Center |  
| Ephrat Levy-Lahad, MD |  
| The Roz and Les Goldstein Award |  
| Tel Aviv University |  
| Ilan Tsarfaty, PhD |  
| **ITALY**           |  |
| Hospital of Prato, Instituto Toscani Tumori |  
| Laura Biganzoli, MD, PhD |  
| The Estée Lauder Companies North America Supply Chain & Operating Facilities Award |  
| Angelo Di Leo, MD, PhD |  
| **PALESTINIAN AUTHORITY** |  |
| Bethlehem University |  
| Moien Kanaan, PhD |  
| The Roz and Les Goldstein Award |  
| **PORTUGAL**        |  |
| Champalimaud Cancer Center |  
| Fatima Cardoso, MD |  
| The Play for P.I.N.K. Award |  
| on behalf of EORTC/TBCRC/BIG/NABCG |  
| **RWANDA**          |  |
| Butaro Hospital |  
| Tharcisse Mpunga, MD |  
| **SPAIN**           |  |
| Vall D’Hebron Institute of Oncology |  
| Joaquin Arribas, PhD |  
| **SWITZERLAND**    |  |
| International Breast Cancer Study Group |  
| Meredith Regan, ScD |  
| The Ann INC. Award, ANN INC. is a division of ascena retail group inc. |  
| **UNITED KINGDOM**  |  |
| Brighton and Sussex Medical School, Shore-C |  
| Dame Lesley Fallowfield, DBE, BSc, DPhil, MedSci |  
| The Estée Lauder Companies Brands Award in Memory of Evelyn H. Lauder |  
| Queen Mary, University of London |  
| Jack Cuzick, BSc, MSc, PhD |  
| The Delta Air Lines Award |  
| on behalf of Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) |  
| Royal Marsden Hospital |  
| Mitch Dowsett, FMedSci, PhD |  
| The Estée Lauder Companies Brands Award in Honor of Elizabeth Hurley |  
| Ian Smith, MD, FRCP, FRCPE |  
| The Estée Lauder Companies Brands Award in Honor of Elizabeth Hurley |  
| The Francis Crick Institute/ The Rockefeller University |  
| Sir Paul Nurse, PhD, FRSS |  
| The Sir Elton John Award |  
| University of Cambridge |  
| Kerstin Meyer, BSc, PhD |  
| Sir Bruce Ponder, FRCP, FMedSci, FRSS |  
| University of Oxford |  
| Adrian Harris, MD, DPhil |  
| The Housewares Charity Foundation Award |  
| University College of London Cancer Institute |  
| Charles Swanton, MD, PhD |  
| The Hamptons Paddle & Party for Pink Award |  
| **WASHINGTON**     |  |
| Fred Hutchinson Cancer Research Center |  
| Nancy Davidson, MD |  
| The ANN INC. Award, ANN INC. is a division of ascena retail group inc. |  
| Cyrus Ghajar, PhD |  
| Anne McTiernan, MD, PhD |  
| The Delta Air Lines Award |  
| Peggy Porter, MD |  
| The Play for P.I.N.K. Award |  
| on behalf of EORTC/TBCRC/BIG/NABCG |  

*As of January 2017*
In 2016-2017, BCRF is investing $57 million to support the work of more than 250 scientists at leading medical and academic institutions across 14 countries, making BCRF the largest private funder of breast cancer research worldwide. By committing 91 cents of every dollar directly to its mission, BCRF remains one of the nation’s most fiscally responsible nonprofits.

BCRF has been recognized as one of the most financially efficient nonprofits in the country.

BCRF has earned the highest rating of 4 stars from Charity Navigator for the 14th time since 2002.

CharityWatch has designated BCRF an “A+” charity, the highest possible rating. BCRF is currently the only breast cancer organization in the U.S. to hold this top ranking.

**STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2016**

**PUBLIC SUPPORT AND REVENUE**

**PUBLIC SUPPORT:**
- Contributions $53,497,039
- Special Events $15,334,356
- Less: Direct benefit to donor costs ($2,494,743)
- Total public support $66,336,652

**REVENUE:**
- Grant refunds $232,080
- Net investment loss $(126,411)
- Foreign currency loss $(69,072)
- Total revenue $36,597
- Total public support and revenue $66,373,249

**EXPENSES:**
- Program Services $60,627,698
- Management and General $2,275,265
- Fundraising $5,458,170
- Total expenses $68,361,133
- Change in net assets $(1,987,884)

**STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2016**

**ASSETS:**
- Cash $40,122,628
- Pledges receivable $10,556,902
- Investments $40,373,118
- Prepaid expenses and other receivables $712,415
- Property and equipment, net $110,350
- Security Deposit $40,061
- Total assets $91,915,474

**LIABILITIES AND NET ASSETS:**
- Liabilities:
  - Accounts payable and accrued expenses $320,165
  - Grants Payable $69,730,204
- Total liabilities $70,050,369

- Net assets:
  - Unrestricted $18,497,961
  - Temporarily Restricted $1,817,144
  - Permanently Restricted $1,550,000
- Total net assets $21,865,105
- Total liabilities and net assets $91,915,474